Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

vudalimab

Phase 2Monoclonal antibody

vudalimab is one of 27 biologic programs targeting Malignancies. It is currently in Phase 2.

1

Indications

4

Total Trials

1

Active Trials

26

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesActive, not recruiting

MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Malignancies

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Fludara

Cellcept

Eloxatin

Prograf

VVeloxis Pharmaceuticals

Fluoropyrimidine

Gemzar

Johnson & Johnson

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tuoyi

CCoherus Oncology, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·XXencor, Inc.·Phase 2·NCT05005728·72 enrolled

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Terminated·EEmory University·Phase 1·NCT05733351·4 enrolled

Malignancies1 trial

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Active, not recruiting·XXencor, Inc.·Phase 2·NCT05032040·170 enrolled

Locally Advanced Thyroid Gland Anaplastic Carcinoma1 trial

A Phase II, Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer

Suspended·NNorthwestern University·Phase 2·NCT05453799·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for vudalimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vudalimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vudalimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xencor, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: XXencor, Inc.

Related News